| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| 250mg | |||
| Other Sizes |
| Targets |
Episyringaresinol 4'-O-β-D-glucopyranoside targets inflammatory pathways in microglial cells, specifically inhibiting nitric oxide production in LPS-stimulated N9 microglial cells. The compound has an IC₅₀ of 91.50 μM for this inhibitory effect. Its mechanism of action is believed to involve the suppression of inducible nitric oxide synthase (iNOS) expression or activity, thereby reducing the production of the pro-inflammatory mediator nitric oxide. The compound may also modulate other inflammatory signaling pathways, though the exact molecular targets have not been fully elucidated.
|
|---|---|
| ln Vitro |
At an IC50 of 91.50 μM, episyringaresinol 4'-O-β-D-glncopyranoside markedly and dose-dependently reduced LPS-induced NO generation in N9 microglia.
In vitro, episyringaresinol 4'-O-β-D-glucopyranoside dramatically inhibits nitric oxide production in LPS-induced N9 microglial cells in a dose-independent manner with an IC₅₀ of 91.50 μM. This indicates potent anti-neuroinflammatory activity. The compound's ability to suppress NO production suggests it may be useful for studying neuroinflammatory conditions. However, no other in vitro activities have been reported for this compound. The compound is a natural potential neuroinflammatory inhibitor and has been investigated for potential roles in liver protection, cancer therapy, and cardiovascular health. |
| ln Vivo |
In vivo activity of episyringaresinol 4'-O-β-D-glucopyranoside has not been extensively characterized in animal models. No specific in vivo studies have been reported for this compound. The compound has been investigated for potential therapeutic applications, but the lack of in vivo data limits the current understanding of its efficacy and safety. Further studies are needed to evaluate its pharmacological effects in vivo, including its anti-inflammatory and neuroprotective activities. The compound is primarily studied in vitro as a natural product with potential therapeutic applications.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for episyringaresinol 4'-O-β-D-glucopyranoside have not been extensively developed or reported in the literature. The compound's primary reported activity is inhibition of NO production in LPS-stimulated N9 microglial cells. In these studies, N9 microglial cells are cultured and stimulated with lipopolysaccharide (LPS) to induce an inflammatory response. The compound is added to the culture medium at various concentrations, and nitric oxide production is measured by the Griess assay. The IC₅₀ value of 91.50 μM is determined by nonlinear regression analysis of the concentration-response curve.
|
| Cell Assay |
In vitro cell-based assays for episyringaresinol 4'-O-β-D-glucopyranoside typically employ N9 microglial cells (a murine microglial cell line). Cells are cultured in appropriate medium (e.g., DMEM supplemented with fetal bovine serum and antibiotics) and plated in multi-well plates. Cells are pretreated with various concentrations of the compound (typically 1-200 μM) for a period of time (e.g., 1-2 hours) before stimulation with LPS (typically 1 μg/mL). After incubation for 18-24 hours, culture supernatants are collected for measurement of NO production by the Griess assay. Cell viability is assessed by MTT or CCK-8 assay to ensure that the observed effects are not due to cytotoxicity.
|
| Animal Protocol |
In vivo animal studies have not been reported for episyringaresinol 4'-O-β-D-glucopyranoside. No animal models have been used to evaluate its pharmacokinetics, efficacy, or toxicology. The compound is primarily studied in vitro as a natural product with potential anti-neuroinflammatory activity. Future studies may involve administration of the compound in rodent models of neuroinflammation, such as LPS-induced systemic inflammation or experimental autoimmune encephalomyelitis, to evaluate its therapeutic potential. Currently, no in vivo data are available.
|
| ADME/Pharmacokinetics |
Pharmacokinetic (PK) properties of episyringaresinol 4'-O-β-D-glucopyranoside have not been characterized. No absorption, distribution, metabolism, or excretion studies have been conducted for this compound. As a natural glycoside, the compound may undergo deglycosylation in the gastrointestinal tract or liver, potentially releasing the aglycone episyringaresinol. However, these properties have not been experimentally determined. The compound's PK profile remains unknown, and further studies are needed to evaluate its bioavailability, half-life, and metabolic stability.
|
| Toxicity/Toxicokinetics |
The toxicity profile of episyringaresinol 4'-O-β-D-glucopyranoside has not been extensively characterized in preclinical studies. No acute toxicity, genotoxicity, or chronic toxicity studies have been reported. The compound is a natural product derivative and is generally considered to have low toxicity, but specific toxicology data are not available. Standard safety precautions should be followed when handling this compound. The compound is intended for research use only and is not approved for human therapeutic applications.
|
| References | |
| Additional Infomation |
According to reports, episyringin 4'-O-β-D-glucopyranoside has been found in Magnolia officinalis, Salix chinensis, and other organisms with available data.
Episyringaresinol 4'-O-β-D-glucopyranoside is a research-grade natural product isolated from Alhagi sparsifolia Shap. It has been identified as a potential neuroinflammatory inhibitor, with an IC₅₀ of 91.50 μM for inhibition of NO production in LPS-induced N9 microglial cells. The compound has also been investigated for potential roles in liver protection, cancer therapy, and cardiovascular health. It is not an approved therapeutic drug and has no clinical trial history. The compound is supplied as a high-purity powder (≥98%) and should be stored appropriately. Molecular formula: C₂₈H₃₆O₁₃; molecular weight: 580.58. |
| Molecular Formula |
C₂₈H₃₆O₁₃
|
|---|---|
| Molecular Weight |
580.58
|
| Exact Mass |
580.215
|
| CAS # |
137038-13-2
|
| PubChem CID |
45482321
|
| Appearance |
White to off-white solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
778.5±60.0 °C at 760 mmHg
|
| Flash Point |
424.6±32.9 °C
|
| Vapour Pressure |
0.0±2.8 mmHg at 25°C
|
| Index of Refraction |
1.601
|
| LogP |
-1.6
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
13
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
41
|
| Complexity |
807
|
| Defined Atom Stereocenter Count |
9
|
| SMILES |
COC1=CC(=CC(=C1O)OC)[C@H]2[C@@H]3CO[C@H]([C@@H]3CO2)C4=CC(=C(C(=C4)OC)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)CO)O)O)O)OC
|
| InChi Key |
WEKCEGQSIIQPAQ-FKLBZQFOSA-N
|
| InChi Code |
InChI=1S/C28H36O13/c1-34-16-5-12(6-17(35-2)21(16)30)25-14-10-39-26(15(14)11-38-25)13-7-18(36-3)27(19(8-13)37-4)41-28-24(33)23(32)22(31)20(9-29)40-28/h5-8,14-15,20,22-26,28-33H,9-11H2,1-4H3/t14-,15-,20-,22-,23+,24-,25+,26+,28+/m1/s1
|
| Chemical Name |
(2S,3R,4S,5S,6R)-2-[4-[(3R,3aS,6R,6aS)-3-(4-hydroxy-3,5-dimethoxyphenyl)-1,3,3a,4,6,6a-hexahydrofuro[3,4-c]furan-6-yl]-2,6-dimethoxyphenoxy]-6-(hydroxymethyl)oxane-3,4,5-triol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~172.24 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.5 mg/mL (4.31 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (4.31 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (4.31 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.7224 mL | 8.6121 mL | 17.2242 mL | |
| 5 mM | 0.3445 mL | 1.7224 mL | 3.4448 mL | |
| 10 mM | 0.1722 mL | 0.8612 mL | 1.7224 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
